Ligand Reports Second Quarter 2017 Financial Results
Ligand to Report Second Quarter 2017 Results on August 7th
Ligand Enters Into Commercial License and Supply Agreement with Amgen for Rights to Use Captisol in the Formulation of AMG 330
Ligand’s Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Surface Oncology
Ligand Announces Aziyo Biologics Acquires Commercial Products from Partner CorMatrix
Ligand Enters Into Worldwide OmniAb® Platform License Agreement With xCella Biosciences
Ligand to Participate in Two Upcoming Investor Conferences
Ligand Reports First Quarter 2017 Financial Results
